COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Feasibility and Efficacy of BACOPP-21 for Patients > 60 Years With Intermediate or Advanced Hodgkins Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00284271
Recruitment Status : Completed
First Posted : January 31, 2006
Last Update Posted : July 29, 2011
Information provided by:
University of Cologne

Brief Summary:
This study is designed to test (1) feasibility and efficiancy of new BACOPP regimen and (2) toxicity, overall response and FFTF.

Condition or disease Intervention/treatment Phase
Hodgkin´s Lymphoma Drug: Cyclophosphamide Drug: Adramycin Drug: Procarbacine Drug: Prednisone Drug: Vincristine Drug: Bleomycin Drug: Erythropoietin beta Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 65 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : January 2004
Actual Primary Completion Date : December 2005

Resource links provided by the National Library of Medicine

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   61 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Hodgkin´s lymphoma (histologically proven)
  • CS (PS) I and II with one of the risk factors a-d

    1. bulky mediastinal mass (> 1/3 maximum transverse thorax diameter)
    2. extranodal involvement
    3. ESR > 50 (A), > 30 (B-symptoms)
    4. 3 or more lymph node areas involved
  • CS (PS) III and IV
  • Written informed consent

Exclusion Criteria:

  • Leukocytes <3000/microl
  • Platelets <100000/microl
  • Hodgkin´s Disease as "composite lymphoma"
  • Activity index (WHO) < grade 2

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00284271

Layout table for location information
University of Cologne
Cologne, Germany, 50931
Sponsors and Collaborators
University of Cologne
Layout table for investigator information
Principal Investigator: Andreas Josting, Dr. University of Cologne
Publications of Results:
Layout table for additonal information Identifier: NCT00284271    
Other Study ID Numbers: BACOPP-21
First Posted: January 31, 2006    Key Record Dates
Last Update Posted: July 29, 2011
Last Verified: July 2011
Keywords provided by University of Cologne:
Hodgkin´s Lymphoma
eldery patients
primary diagnosis
Additional relevant MeSH terms:
Layout table for MeSH terms
Hodgkin Disease
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Epoetin Alfa
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents, Phytogenic
Tubulin Modulators
Antimitotic Agents